Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	39.23	31.23	51.83	18.82	63.51
Cash & Cash Equivalents	39.23	31.23	51.83	18.82	63.51
Cash Growth	25.62%	-39.74%	175.39%	-70.37%	-18.28%
Other Current Assets	1.13	1.72	17.13	1.01	7.62
Total Current Assets	40.36	32.95	68.96	19.83	71.13
Property, Plant & Equipment	10.79	12.71	4.16	2.99	3.33
Other Long-Term Assets	0.45	0.43	0.11	0.05	0.51
Total Long-Term Assets	11.24	13.14	4.28	3.04	3.84
Total Assets	51.6	46.09	73.24	22.86	74.97
Accounts Payable	0.85	1.11	0.99	1.07	1.5
Current Debt	5.24	1.41	1.44	0.71	1.96
Other Current Liabilities	3.33	4.76	17.59	1.44	9.07
Total Current Liabilities	9.41	7.28	20.03	3.22	12.52
Long-Term Debt	15.42	20.7	17.1	1.73	2.56
Other Long-Term Liabilities	0	0	0	0	0.02
Total Long-Term Liabilities	15.42	20.7	17.1	1.73	2.58
Total Liabilities	24.84	27.98	37.12	4.95	15.1
Total Debt	20.66	22.11	18.54	2.44	4.52
Debt Growth	-6.57%	19.30%	660.02%	-46.06%	690.56%
Retained Earnings	-165.26	-135.77	-100.06	-71.76	-208.65
Comprehensive Income	0	0	0	0	0.17
Shareholders' Equity	26.77	18.11	36.12	-68.79	58.55
Net Cash / Debt	18.57	9.12	33.29	16.38	58.99
Net Cash / Debt Growth	103.70%	-72.62%	103.24%	-72.23%	-23.53%
Net Cash Per Share	1.20	0.79	8.78	34.99	64.56
Working Capital	30.95	25.67	48.94	16.6	58.61
Book Value Per Share	1.74	1.57	9.53	-146.94	64.07

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).